-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Here's Why I Think Guiyang Xintian PharmaceuticalLtd (SZSE:002873) Might Deserve Your Attention Today
Here's Why I Think Guiyang Xintian PharmaceuticalLtd (SZSE:002873) Might Deserve Your Attention Today
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it completely lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses.
In contrast to all that, I prefer to spend time on companies like Guiyang Xintian PharmaceuticalLtd (SZSE:002873), which has not only revenues, but also profits. Even if the shares are fully valued today, most capitalists would recognize its profits as the demonstration of steady value generation. Loss-making companies are always racing against time to reach financial sustainability, but time is often a friend of the profitable company, especially if it is growing.
View our latest analysis for Guiyang Xintian PharmaceuticalLtd
Guiyang Xintian PharmaceuticalLtd's Earnings Per Share Are Growing.
If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS). It's no surprise, then, that I like to invest in companies with EPS growth. Over the last three years, Guiyang Xintian PharmaceuticalLtd has grown EPS by 13% per year. That growth rate is fairly good, assuming the company can keep it up.
I like to take a look at earnings before interest and (EBIT) tax margins, as well as revenue growth, to get another take on the quality of the company's growth. Guiyang Xintian PharmaceuticalLtd maintained stable EBIT margins over the last year, all while growing revenue 29% to CN¥970m. That's progress.
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
SZSE:002873 Earnings and Revenue History April 15th 2022While profitability drives the upside, prudent investors always check the balance sheet, too.
Are Guiyang Xintian PharmaceuticalLtd Insiders Aligned With All Shareholders?
Personally, I like to see high insider ownership of a company, since it suggests that it will be managed in the interests of shareholders. So as you can imagine, the fact that Guiyang Xintian PharmaceuticalLtd insiders own a significant number of shares certainly appeals to me. In fact, they own 45% of the shares, making insiders a very influential shareholder group. I'm reassured by this kind of alignment, as it suggests the business will be run for the benefit of shareholders. In terms of absolute value, insiders have CN¥1.2b invested in the business, using the current share price. That's nothing to sneeze at!
Is Guiyang Xintian PharmaceuticalLtd Worth Keeping An Eye On?
One important encouraging feature of Guiyang Xintian PharmaceuticalLtd is that it is growing profits. If that's not enough on its own, there is also the rather notable levels of insider ownership. That combination appeals to me, for one. So yes, I do think the stock is worth keeping an eye on. You should always think about risks though. Case in point, we've spotted 2 warning signs for Guiyang Xintian PharmaceuticalLtd you should be aware of.
You can invest in any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it completely lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses.
对于初学者来说,收购一家向投资者讲述一个好故事的公司似乎是一个好主意(也是一个令人兴奋的前景),即使它完全没有收入和利润的记录。但现实是,当一家公司每年亏损时,在足够长的时间内,投资者通常会承担他们的损失份额。
In contrast to all that, I prefer to spend time on companies like Guiyang Xintian PharmaceuticalLtd (SZSE:002873), which has not only revenues, but also profits. Even if the shares are fully valued today, most capitalists would recognize its profits as the demonstration of steady value generation. Loss-making companies are always racing against time to reach financial sustainability, but time is often a friend of the profitable company, especially if it is growing.
与此形成对比的是,我更喜欢把时间花在像贵阳新天药业有限公司(上证所:002873),不仅有收入,而且有利润。即使股票在今天得到了充分的估值,大多数资本家也会认为它的利润是创造稳定价值的证明。亏损的公司总是在与时间赛跑,以实现财务上的可持续性,但时间往往是盈利公司的朋友,特别是如果它还在增长的话。
View our latest analysis for Guiyang Xintian PharmaceuticalLtd
查看我们对贵阳新天药业有限公司的最新分析
Guiyang Xintian PharmaceuticalLtd's Earnings Per Share Are Growing.
贵阳新天药业股份有限公司的每股收益正在增长。
If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS). It's no surprise, then, that I like to invest in companies with EPS growth. Over the last three years, Guiyang Xintian PharmaceuticalLtd has grown EPS by 13% per year. That growth rate is fairly good, assuming the company can keep it up.
如果你相信市场是模糊有效的,那么从长期来看,你会认为一家公司的股价会跟随其每股收益(EPS)。因此,我喜欢投资每股收益增长的公司也就不足为奇了。在过去的三年里,贵阳新天制药有限公司的每股收益以每年13%的速度增长。假设该公司能够保持这一增速,那么这个增速已经相当不错了。
I like to take a look at earnings before interest and (EBIT) tax margins, as well as revenue growth, to get another take on the quality of the company's growth. Guiyang Xintian PharmaceuticalLtd maintained stable EBIT margins over the last year, all while growing revenue 29% to CN¥970m. That's progress.
我喜欢看看息税前利润(EBIT)和收入增长,以了解公司增长的质量。贵阳新天医药有限公司去年保持稳定的息税前利润,同时收入增长29%,达到人民币9.7亿元。这就是进步。
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
下面的图表显示了该公司的利润和收入是如何随着时间的推移而变化的。点击图表查看确切的数字。
While profitability drives the upside, prudent investors always check the balance sheet, too.
虽然盈利能力推动了上行,但谨慎的投资者总是会检查资产负债表。
Are Guiyang Xintian PharmaceuticalLtd Insiders Aligned With All Shareholders?
贵阳新天药业内部人士是否与所有股东一致?
Personally, I like to see high insider ownership of a company, since it suggests that it will be managed in the interests of shareholders. So as you can imagine, the fact that Guiyang Xintian PharmaceuticalLtd insiders own a significant number of shares certainly appeals to me. In fact, they own 45% of the shares, making insiders a very influential shareholder group. I'm reassured by this kind of alignment, as it suggests the business will be run for the benefit of shareholders. In terms of absolute value, insiders have CN¥1.2b invested in the business, using the current share price. That's nothing to sneeze at!
就我个人而言,我喜欢看到一家公司拥有较高的内部人所有权,因为这意味着它的管理将符合股东的利益。因此,你可以想象到,贵阳新天医药有限公司内部人士持有大量股份的事实肯定对我有吸引力。事实上,他们拥有45%的股份,使内部人士成为一个非常有影响力的股东群体。我对这种调整感到放心,因为这表明公司将为股东的利益而运营。以绝对值计算,按目前股价计算,内部人士在该业务上投资12亿元。这可不是小菜一碟!
Is Guiyang Xintian PharmaceuticalLtd Worth Keeping An Eye On?
贵阳新天药业值得关注吗?
One important encouraging feature of Guiyang Xintian PharmaceuticalLtd is that it is growing profits. If that's not enough on its own, there is also the rather notable levels of insider ownership. That combination appeals to me, for one. So yes, I do think the stock is worth keeping an eye on. You should always think about risks though. Case in point, we've spotted 2 warning signs for Guiyang Xintian PharmaceuticalLtd you should be aware of.
贵阳新天药业有限公司一个重要的令人鼓舞的特点是它的利润在增长。如果这本身还不够,还有相当显著的内部人持股水平。例如,这种组合对我很有吸引力。因此,是的,我确实认为这只股票值得关注。不过,你应该始终考虑风险。举个例子,我们发现了贵阳新天制药有限公司的两个警示标志,你应该注意。
You can invest in any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.
你可以投资任何你想投资的公司。但如果你更愿意关注那些表现出内幕收购的股票,这里有一份过去三个月内有内幕收购的公司名单。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
请注意,本文中讨论的内幕交易指的是相关司法管辖区内的应报告交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗?保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
这篇由《华尔街日报》撰写的文章本质上是笼统的。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。简单地说,华尔街在提到的任何股票中都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧